Navigation Links
Exagen's Corporate Expansion Creates Job Opportunities in New Mexico
Date:1/25/2011

ALBUQUERQUE, N.M., Jan. 25, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, announced today the completion of the company's office expansion at the University of New Mexico Science and Technology Park. The expansion, which includes new space for both offices and a laboratory, allows Exagen to accommodate growing test volume for its gastroenterology products and the transition of the company's newly acquired rheumatology diagnostic products to Albuquerque.

"We are pleased to see the rapid adoption of our gene expression tests for the diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome," said Scott Glenn, Exagen CEO. "New Mexico is a wonderful environment to build a business, and our success will create an ongoing need for employees in operations, research and development, sales and marketing."

In the coming year, Exagen plans to double its sales force and hire 16 additional employees, including technical lab personnel, marketing directors, customer service and billing staff. Sales force personnel will be geographically based; all others will be based in Albuquerque.

In addition to commercial laboratory testing, Exagen has an active Research and Development group that will use some of the new space to complete various programs in both rheumatology and gastroenterology. With a commitment to personalized medicine, Exagen is focused on discovering and developing tests for individualized diagnostic information. A number of products are expected to be launched in 2011 and 2012.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed diagnostic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Incorporated Announces Third Quarter 2007 Financial Results
3. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
4. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):